Dynavax Technologies Corporation (OQ:DVAX)

Business Focus: Bio Therapeutic Drugs

Jul 14, 2020 08:00 am ET
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, announced today that the first participants have been dosed in the Phase 1 clinical trial evaluating Medicago’s...
Jul 10, 2020 04:01 pm ET
Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes
Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, and Times Pharmacy, have partnered with Hep Free Hawaii to provide HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] at...
Jul 08, 2020 08:30 am ET
Dynavax and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate
EMERYVILLE, CA and QUEBEC CITY, CANADA / ACCESSWIRE / July 8, 2020 / Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Medicago, a biopharmaceutical company creating vaccines and therapeutics by leveraging innovative plant-based technologies, today announced their collaboration to investigate an adjuvanted vaccine candidate to protect against COVID-19. The collaboration is evaluating the combination of Medicag
Jun 26, 2020 09:31 am ET
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney?
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS....
Jun 24, 2020 09:31 am ET
Thinking about buying stock in Trevena, Translate Bio, Workhorse Group, Dynavax Technologies, or Seelos Therapeutics?
NEW YORK, June 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRVN, TBIO, WKHS, DVAX, and SEEL....
Jun 22, 2020 09:00 am ET
Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the...
Jun 19, 2020 09:31 am ET
Thinking about buying stock in Salem Media Group, Dynavax Technologies, Celsion Corp, Hertz Global Holdings, or MGM Resorts?
NEW YORK, June 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SALM, DVAX, CLSN, HTZ, and MGM....
Jun 19, 2020 06:00 am ET
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, announced today that the first participants have been dosed in the Phase 1 clinical trial to evaluate Clover...
Jun 09, 2020 08:00 am ET
Dynavax Completes Enrollment of Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has completed enrollment of 119 patients in the clinical trial evaluating HEPLISAV-B®...
Jun 02, 2020 09:31 am ET
Thinking about buying stock in Laredo Petroleum, Moneygram International, Dynavax Technologies, Riot Blockchain, or Allied Esports Entertainment?
NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPI, MGI, DVAX, RIOT, and AESE....
May 29, 2020 09:31 am ET
Thinking about buying stock in Adaptimmune Therapeutics, MEI Pharma, Dynavax Technologies, AIM ImmunoTech, or Meridian Bioscience?
NEW YORK, May 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, MEIP, DVAX, AIM, and VIVO....
May 28, 2020 04:05 pm ET
Dynavax to Present at the William Blair 40th Annual Growth Stock Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the...
May 27, 2020 04:05 pm ET
Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its...
May 21, 2020 09:00 pm ET
Dynavax Technologies Announces Pricing of $70.0 Million Public Offering of Common Stock
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its...
May 21, 2020 04:01 pm ET
Dynavax Technologies Announces Proposed Public Offering of Common Stock
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common...
May 19, 2020 09:31 am ET
Thinking about buying stock in Arbutus Biopharma, Dynavax Technologies, Applied DNA Sciences, Evoke Pharma, or Aphria?
NEW YORK, May 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, DVAX, APDN, EVOK, and APHA....
May 07, 2020 04:10 pm ET
Dynavax Announces First Quarter 2020 Financial Results
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of 2020. “Now more than ever, the world is acutely...
Apr 28, 2020 04:10 pm ET
Dynavax Reports Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported immunogenicity and safety data from an interim analysis of the ongoing clinical trial evaluating...
Apr 23, 2020 04:10 pm ET
Dynavax to Report First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2020 financial results on Thursday, May 7, 2020, after the U.S. financial markets...
Apr 16, 2020 07:30 am ET
Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today...
Apr 08, 2020 08:00 am ET
Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amids
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is donating 10,000 doses of HEPLISAV-B adult vaccine to help protect healthcare professionals...
Apr 02, 2020 04:30 pm ET
Dynavax Provides Business Update on COVID-19 Pandemic Impact
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today provided a business update in relation to the impact of COVID-19 on the Company’s operations. “During the...
Mar 26, 2020 07:30 am ET
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced a collaboration supporting the...
Mar 24, 2020 08:30 am ET
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceuticals, a China-based global clinical-stage biotechnology company focused on developing...
Mar 11, 2020 04:10 pm ET
Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the fourth quarter and full year 2019. “Vaccines offer an unmatched value...
Mar 02, 2020 08:00 am ET
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland (UQ) as part of a Coalition for Epidemic...
Feb 24, 2020 04:05 pm ET
Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report fourth quarter and full year 2019 financial results on Wednesday, March 11, 2020, after the U.S....
Feb 18, 2020 04:05 pm ET
Dynavax to Present at the Cowen 40th Annual Health Care Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Cowen 40th Annual Health Care...
Dec 16, 2019 04:15 pm ET
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer has been appointed Chief Executive Officer and to the Board of Directors. David...
Dec 05, 2019 08:00 am ET
Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Albertsons Companies, one of the largest food and drug retailers in the United States, have partnered to...
Dec 03, 2019 07:00 am ET
Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has filed a report on a cumulative analysis (comprising both required interim analyses)...
Nov 07, 2019 04:05 pm ET
Dynavax to Present at the Stifel 2019 Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Co-President, will present at the Stifel 2019 Healthcare Conference on...
Nov 06, 2019 04:05 pm ET
Dynavax Announces Third Quarter 2019 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the third quarter ended September 30, 2019. “HEPLISAV-B net product revenue...
Oct 24, 2019 04:05 pm ET
Dynavax to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, will report third quarter 2019 financial results on Wednesday, November 6, 2019, after the U.S. financial markets close....
Sep 30, 2019 04:05 pm ET
Dynavax to Present at the 2019 Cantor Global Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the 2019 Cantor Global Healthcare Conference on Friday, Oct. 4, at 12 p.m. E.T. The...
Aug 12, 2019 04:05 pm ET
Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, today announced Andrew A. F. Hack, M.D., Ph.D., a Managing Director at  Bain Capital Life Sciences, has been appointed to...
Aug 08, 2019 08:00 am ET
Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, today announced the pricing of an underwritten public offering of 18,525,000 shares...
Aug 07, 2019 04:12 pm ET
Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock
Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other...
Aug 07, 2019 04:01 pm ET
Dynavax Announces Second Quarter 2019 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines, today reported financial results for the second quarter ended June 30, 2019.   “HEPLISAV-B net product revenue was $8.3...
Jul 24, 2019 04:05 pm ET
Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on developing novel vaccines, will report its second quarter 2019 financial results on Wednesday, August 7, 2019, after the U.S. financial markets...
Jun 03, 2019 04:05 pm ET
Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the William Blair & Co. Annual Growth Stock Conference  on Thursday, June 6, at 9:20...
Jun 03, 2019 02:15 pm ET
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced increasingly favorable results from the Phase 1b/2 (SYNERGY-001), open-label, multicenter study of the combination of SD-101 and KEYTRUDA® (pembrolizumab) in advanced melanoma...
Jun 01, 2019 02:15 pm ET
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced favorable results from the Phase 2 cohort expansion of the Phase 1b/2, open-label, multicenter study of intratumoral SD-101 in combination with KEYTRUDA® (pembrolizumab) in anti-PD-1...
May 23, 2019 04:45 pm ET
Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part...
May 08, 2019 04:05 pm ET
Dynavax Announces First Quarter 2019 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today reported financial results for the first...
May 02, 2019 05:00 pm ET
Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] in Adults With End-Stage Renal Disease
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today announced the enrollment of the first...
Apr 25, 2019 04:05 pm ET
Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its first quarter 2019 financial results on Wednesday,...
Apr 18, 2019 04:05 pm ET
Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present data from a Phase 1b/2 combination...
Apr 11, 2019 07:20 am ET
Investor Expectations to Drive Momentum within Dynavax Technologies, The Trade Desk, Genesco, Kraton, Broadridge Financial Solutions, and Manitex International — Discovering Underlying Factors of Infl
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX), The Trade Desk Inc....
Apr 02, 2019 01:00 pm ET
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced results from the ongoing Phase 1b clinical study...
Apr 01, 2019 01:00 pm ET
Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
Dynavax Technologies Corporation (NASDAQ: DVAX) and 4SC AG (FSE Prime Standard: VSC) today announced the combination of 4SC’s orally available class I selective HDAC inhibitor domatinostat (4SC-202) with Dynavax’s intratumoral TLR9 agonist SD-101...
Mar 28, 2019 04:05 pm ET
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has...
Mar 20, 2019 04:20 pm ET
Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present safety and biomarker data for...
Mar 18, 2019 04:05 pm ET
Dynavax Exercises Option for $75 Million in Non-Dilutive Debt
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has exercised its option to draw down $75 million of non-dilutive capital under its existing term loan agreement with CRG Servicing LLC, a healthcare-focused investment firm....
Mar 06, 2019 04:05 pm ET
Dynavax to Present at 39th Annual Cowen Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray, Chief Executive Officer, will...
Feb 26, 2019 04:05 pm ET
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year...
Feb 12, 2019 04:05 pm ET
Dynavax Technologies to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, will report its fourth quarter and full year 2018 financial results...
Feb 11, 2019 07:20 am ET
Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Corcept Therapeutics Incorporated (NASDAQ:CORT), CDK Global, Inc....
Jan 29, 2019 04:05 pm ET
Heather Rowe Named Dynavax’s Vice President of Investor Relations and Corporate Communications
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Heather Rowe has been appointed vice president...
Jan 08, 2019 09:00 am ET
Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
Dynavax Technologies Corporation (NASDAQ:DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club, a leading membership warehouse club offering superior products, savings and services to millions of...
Jan 03, 2019 04:05 pm ET
Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray, Chief Executive Officer, will...
Nov 08, 2018 08:55 am ET
Consolidated Research: 2018 Summary Expectations for MYR Group, L.B. Foster, The Habit Restaurants, Viper Energy Partners LP, Twin Disc, and Dynavax Technologies — Fundamental Analysis, Key Performanc
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of MYR Group, Inc. (NASDAQ:MYRG), L.B. Foster Company (NASDAQ:FSTR), The...
Nov 05, 2018 04:01 pm ET
Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2018 along with an update on the launch progress of HEPLISAV-B and an overview of recently presented data for SD-101 in...
Oct 29, 2018 06:00 am ET
Dynavax to Host Third Quarter 2018 Financial Results Conference Call
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30, 2018 after market close on Monday, November 5, 2018, and host a conference call that day to review the...
Oct 20, 2018 08:45 am ET
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
Dynavax Technologies Corporation (NASDAQ:DVAX) today presented interim data from its ongoing Phase 1b/2 SYNERGY-001 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy...
Oct 17, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS), Dynavax Technologies Corporation...
Oct 15, 2018 06:00 am ET
Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
Dynavax Technologies Corporation (NASDAQ:DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA® (pembrolizumab) will be...
Oct 09, 2018 06:00 am ET
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1...
Sep 27, 2018 04:01 pm ET
Dynavax to Present at the 2018 Cantor Global Healthcare Conference
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental New...
Sep 04, 2018 06:30 am ET
Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced publication of a preclinical study demonstrating that inhalation of a TLR9 agonist can stimulate effective immunity against lung tumors and complement the actions of PD-1 blockade to...
Aug 28, 2018 06:30 am ET
Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been published by Cancer Discovery, a journal publication from American Association of Cancer Research (AACR)....
Aug 14, 2018 07:45 am ET
Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys — Fundamental Analysis, Key Per
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National Instruments Corporation (NASDAQ:NATI), Dynavax Technologies...
Aug 06, 2018 04:01 pm ET
Dynavax Reports Second Quarter 2018 Financial Results
Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the second quarter ended June 30, 2018. The net loss for the quarter was $39.4 million, or $0.63 per share, compared to $20.3 million, or $0.41 per share, for the...
Jul 30, 2018 02:45 pm ET
Dynavax to Host Second Quarter 2018 Financial Results Conference Call
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the second quarter ended June 30, 2018 after market close on Monday, August 6, 2018, and host a conference call that day to review the results...
Jun 28, 2018 06:30 am ET
Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the formation of a six-member Scientific Advisory Board with significant experience in research, development, and commercialization in the fields of oncology and immunology. Scientific...
Jun 25, 2018 12:05 pm ET
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced results of a post hoc analysis of data from HBV 23, the pivotal Phase 3 trial of its hepatitis B vaccine HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. HBV 23 was a...
Jun 11, 2018 06:30 am ET
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Michael Ostrach, Dynavax’s Chief Financial Officer, will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL. The presentation will be webcast live and...
Jun 04, 2018 02:15 pm ET
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck...
May 16, 2018 05:15 pm ET
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1...
May 16, 2018 08:30 am ET
Market Trends Toward New Normal in Dynavax Technologies, Synergy Resources, Allscripts Healthcare Solutions, Plug Power, GameStop, and Newfield Exploration — Emerging Consolidated Expectations, Analys
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX), Synergy Resources...
May 08, 2018 04:05 pm ET
Dynavax Reports First Quarter 2018 Financial Results
Dynavax Technologies Corporation (NASDAQ:DVAX) today reported financial results for the first quarter ended March 31, 2018. The net loss for the quarter ended March 31, 2018, was $39.0 million, or $0.63 per share, compared to $25.3 million,...
May 07, 2018 06:30 am ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the “Committee”) approved the grant of inducement stock options to purchase an aggregate of 79,000 shares...
May 02, 2018 04:15 pm ET
Dynavax to Host First Quarter 2018 Financial Results Conference Call
Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018, and host a conference call that day to review the results...
Apr 23, 2018 06:30 am ET
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
HEPLISAV-B Now Meets a Critical Reimbursement Requirement for Many Insurance Plans
Apr 17, 2018 09:07 am ET
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
Demonstrates potential to achieve long-term, systemic responses Combination therapy was well tolerated Additional SD-101 data in head and neck squamous cell carcinoma presented at AACR
Apr 16, 2018 02:10 pm ET
Dynavax Reports Interim Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck
BERKELEY, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced data from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® , an anti-PD-1 therapy developed by Merck...
Apr 03, 2018 04:30 pm ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 29, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of (i) inducement stock options to purchase an...
Mar 08, 2018 06:30 am ET
Mar 05, 2018 04:30 pm ET
Dynavax to Present at the Cowen & Co. Annual Health Care Conference
BERKELEY, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s Chief Executive Officer, will present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. The presentation...
Mar 02, 2018 06:30 am ET
Stanley A. Plotkin, M.D. Steps Down from Board of Dynavax Technologies
Dr. Plotkin Will Continue as Scientific Advisor
Mar 01, 2018 04:45 pm ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate...
Feb 21, 2018 09:36 am ET
Feb 20, 2018 06:30 am ET
Dynavax Secures $175 Million in Non-Dilutive Debt Financing
Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company’s Immuno-Oncology Product Candidates
Feb 14, 2018 08:00 am ET
Dynavax to Present at the RBC Capital Markets Global Healthcare Conference
BERKELEY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York...
Feb 02, 2018 04:30 pm ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on February 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of (i) inducement stock options to purchase an...
Feb 02, 2018 07:40 am ET
New Research: Key Drivers of Growth for First Busey, Newtek Business Services, Lakeland Financial, Costco Wholesale, Dynavax Technologies, and Overstock — Factors of Influence, Major Initiatives and S
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Busey Corporation (NASDAQ:BUSE), Newtek Business...
Jan 12, 2018 04:01 pm ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate...
Jan 08, 2018 06:00 am ET
Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults
Jan 04, 2018 06:00 am ET
Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference
BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray, Dynavax’s chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA. The...
Dec 05, 2017 04:01 pm ET
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common...
Nov 28, 2017 07:50 am ET
Report: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming Devel
NEW YORK, Nov. 28, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Starbucks Corporation (NASDAQ:SBUX), Home Depot, Inc....
Nov 27, 2017 04:01 pm ET
Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA. The presentation will be webcast...
Nov 09, 2017 04:45 pm ET
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of...
Nov 03, 2017 06:30 am ET
Dynavax Reports Third Quarter 2017 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at...
Oct 19, 2017 06:30 am ET
Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
Dynavax Technologies Corporation (NASDAQ: DVAX) announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer...
Sep 05, 2017 06:00 am ET
Dynavax to Present at Upcoming Investor Conferences
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September.NewsMakers in the Biotech Industry Investor ConferenceFriday, September 8, 2017 in New York at 8:30 a.m....
Aug 15, 2017 04:01 pm ET
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option...
Aug 09, 2017 08:00 pm ET
Dynavax Prices Public Offering of Common Stock
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share. The gross proceeds to...
Aug 08, 2017 04:05 pm ET
Dynavax Announces Proposed Public Offering of Common Stock
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant...
Aug 03, 2017 04:00 pm ET
Dynavax Provides U.S. Regulatory Update on HEPLISAV-B(TM) Following FDA Advisory Committee Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has requested more detailed information about the company's proposed post-marketing study for HEPLISAV-B™ [Hepatitis B Vaccine,...
Aug 02, 2017 06:00 am ET
Dynavax Reports Second Quarter 2017 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017. Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December...
Jul 28, 2017 04:35 pm ET
Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B(TM)
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B...
Jun 23, 2017 04:48 pm ET
Lifshitz & Miller LLP Files Amended Shareholder Derivative Lawsuit on Behalf of Dynavax Technologies Corporation
NEW YORK, June 23, 2017 /PRNewswire/ -- Lifshitz & Miller, a law firm focused on representing shareholders nationwide in shareholder derivative litigation and securities class actions, announces that on February 16, 2017, Lifshitz & Miller filed a shareholder derivative action on behalf of Dynavax Technologies Corporation ("Dynavax" or the "Company")(NASDAQ: DVAX).  Lifshitz & Miller filed an amended complaint on May 5, 2017....
Jun 02, 2017 04:01 pm ET
Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA(R) (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in...
May 19, 2017 06:00 am ET
Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy...
May 08, 2017 06:00 am ET
Dynavax Reports First Quarter 2017 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2017. Cash, cash equivalents and marketable securities were $85.4 million at March 31, 2017 compared to $81.4 million at December...
Apr 03, 2017 06:00 am ET
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has informed the company that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review HEPLISAV-B™...
Mar 20, 2017 06:00 am ET
Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 (TLR9) agonists at the 2017 American Association for Cancer...
Mar 13, 2017 06:00 am ET
Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 per share, compared to $106.8...
Mar 06, 2017 08:00 am ET
Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in...
Mar 02, 2017 06:00 am ET
Dynavax to Present at the Cowen and Company 37th Annual Health Care Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast...
Feb 28, 2017 04:01 pm ET
Dynavax Announces FDA Acceptance for Review of Its Complete Response to November 2016 CRL and PDUFA Action Date for HEPLISAV-B(TM)
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics...
Feb 16, 2017 06:00 am ET
Dynavax to Present at the 2017 RBC Capital Markets Global Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York, NY....
Jan 09, 2017 07:00 am ET
Dynavax to Present at J.P. Morgan 35th Annual Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 35th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast...
Jan 05, 2017 12:35 pm ET
Dynavax Restructures and Emphasizes Immuno-Oncology Program
Dynavax Technologies Corporation (NASDAQ: DVAX), a clinical-stage biopharmaceutical company, today announced that it is reshaping its strategy and operations to prioritize its emerging clinical and preclinical immuno-oncology portfolio. The company...
Jan 03, 2017 12:03 pm ET
DVAX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dynavax Technologies Corporation and a Lead Plaintiff Deadline of January 17, 2017
NEW YORK, Jan. 3, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ: DVAX) securities between March 10, 2014 and November 11, 2016....
Dec 20, 2016 02:05 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact Brower Piven Before The Lead Plaintiff Deadlin
STEVENSON, Md., Dec. 20, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Dynavax Technologies Corporation (Nasdaq:DVAX) (“Dynavax” or the “Company”) common shares during the period between March 10, 2014 and November 11, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until January 17, 2017 to seek appointment as ...
Dec 05, 2016 07:00 am ET
Dynavax Presents Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, in Combination with Targeted Low-Dose Radiation, at ASH Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2, two-part clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lymphoma. The combination of intratumoral...
Dec 02, 2016 08:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Dynavax Technologies Corporation of Class Action Lawsuit and Upcoming Deadline – DVAX
NEW YORK, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ:DVAX) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-06690, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Dynavax securities between March 10, 2014 and November 11, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages cause...
Dec 01, 2016 07:00 am ET
Dynavax to Webcast Cancer R&D Day on December 9, 2016
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will hold a Research and Development (R&D) Day in New York City next week where it will showcase its immuno-oncology program. The event, which is for institutional...
Nov 30, 2016 07:00 am ET
Dynavax to Present Clinical Data from Immuno-oncology Product Candidate, SD-101
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma. The poster presentation...
Nov 28, 2016 10:41 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dynavax Technologies Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 - DVAX
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Dynavax Technologies Corporation (NASDAQ: DVAX) between March 10, 2014 and November 11, 2016. You are...
Nov 27, 2016 06:00 am ET
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Dynavax Technologies Corporation To Contact Bro
STEVENSON, Md., Nov. 27, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Dynavax Technologies Corporation (Nasdaq:DVAX) (“Dynavax” or the “Company”) common shares during the period between March 10, 2014 and November 11, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until January 17, 2017 to seek appointment as ...
Nov 25, 2016 08:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Dynavax Technologies Corporation of Class Action Lawsuit and Upcoming Deadline - DVAX
NEW YORK, Nov. 25, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ:  DVAX) and certain of its officers.  The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-06690, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Dynavax securities between March 10, 2014 and November 11, 2016, both dates inclusive (the "Class Period"), seeking to recover compensable damages caused b...
Nov 21, 2016 07:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Dynavax Technologies Corporation (DVAX)
NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (Nasdaq:DVAX) in the United States District Court for the Northern District of California on behalf of purchasers of common stock of Dynavax between March 10, 2014 through November 11, 2016 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934....
Nov 21, 2016 03:15 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Dynavax Technologies Corporation (DVAX) & Lead Plaintiff Deadline: January 17, 2017
NEW YORK, Nov. 21, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Dynavax Technologies Corporation ("Dynavax" or the "Company") (DVAX) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Dynavax securities March 10, 2014 and November 11, 2016 both dates inclusive (the "Class Period"). Such investors are advised to join this case by visiting the firm's site: www.bgandg.com/dvax. ...
Nov 18, 2016 06:55 pm ET
Nov 18, 2016 04:55 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Dynavax Technologies Corporation and Certain Officers – DVAX
NEW YORK, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NASDAQ:DVAX) and certain of its officers. The class action, filed in United States District Court, Northern District of California, and docketed under 16-cv-06690, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Dynavax securities between March 10, 2014 and November 11, 2016, both dates inclusive (the “Class Period”), seeking to recover compensable damages cause...
Nov 14, 2016 06:02 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dynavax Technologies Corporation (DVAX)
NEW YORK, Nov. 14, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/dvax....
Nov 14, 2016 06:30 am ET
Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration for Biologics License Application for HEPLISAV-B
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B...
Nov 09, 2016 11:00 am ET
Dynavax Presents Early Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, at Society for Melanoma Research
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1...
Nov 07, 2016 06:00 am ET
Dynavax Reports Third Quarter 2016 Financial Results and Company Update
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter and nine months ended September 30, 2016.The Company had $109.6 million in cash, cash equivalents and marketable securities as of September 30,...
Oct 27, 2016 07:00 am ET
Dynavax Secures Committed Financing From Deerfield for $100 Million of Senior Secured Notes
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has entered into a note purchase agreement with one or more funds of Deerfield Management Company, L.P, pursuant to which Dynavax has agreed to sell, and Deerfield has agreed to...
Oct 26, 2016 09:00 am ET
Dynavax Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection in Populations Known to Have a Reduced Immune Response to Currently Licen
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced sub-group results from HBV-23, the pivotal Phase 3 trial of its investigational hepatitis B vaccine HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)]. The new subgroup...
Oct 18, 2016 09:30 am ET
Oct 09, 2016 07:00 am ET
Dynavax Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ESMO Annual Congress
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the first presentation of findings from an ongoing Phase 1/2 study evaluating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with Keytruda ® (pembrolizumab), Merck's anti-PD-1...
Sep 06, 2016 11:15 am ET
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dynavax Technologies Corporation (DVAX)
NEW YORK, Sept. 6, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Dynavax Technologies Corporation ("Dynavax" or the "Company") (NASDAQ: DVAX). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. ...
Sep 04, 2016 08:20 pm ET
Dynavax Provides Regulatory Update on HEPLISAV-B
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16, 2016, Vaccines and Related Biological Products...
Aug 05, 2016 05:51 pm ET
Dynavax Reports Second Quarter 2016 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter and six months ended June 30, 2016.The Company had $139.0 million in cash, cash equivalents and marketable securities as of June 30, 2016,...
Aug 05, 2016 05:31 pm ET
Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the Vaccines and Related Biological Products Advisory Committee (VBRPAC) will review the Biologics License Application (BLA) for HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant...
Jun 11, 2016 11:00 am ET
Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B(TM), in Adults With Type 2 Diabetes at ADA Scientific Sessions
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced preliminary results from a pivotal Phase 3 trial demonstrating that HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] provided a significantly higher rate of seroprotection...
May 18, 2016 07:00 am ET
Dynavax to Present at Two Upcoming Investor Conferences
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present at two upcoming investor conferences. Information relating to the two presentations follows: 2016 UBS Global Healthcare Conference Michael Ostrach,...
May 09, 2016 09:00 am ET
Dynavax Reports First Quarter 2016 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2016.The Company had $166.8 million in cash, cash equivalents and marketable securities as of March 31, 2016, compared to $196.1...
Apr 27, 2016 07:00 am ET
Dynavax Receives Notification of PDUFA Extension for HEPLISAV-B to December 15, 2016
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B™, Dynavax's...
Apr 18, 2016 04:02 pm ET
Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in...
Apr 18, 2016 04:02 pm ET
Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced results from HBV-23, a pivotal Phase 3 trial that provides head-to-head safety and immunogenicity data comparing its investigational adult hepatitis B vaccine, HEPLISAV-B, with the...
Apr 04, 2016 07:00 am ET
Dynavax to Present Data From Pivotal Phase 3 HEPLISAV-B(TM) Trial
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present HEPLISAV-B pivotal Phase 3 data at the National Foundation for Infectious Diseases' 19th Annual Conference on Vaccine Research (ACVR). The Conference will take...
Mar 30, 2016 05:13 pm ET
Dynavax Announces FDA Acceptance for Review of Biologics License Application and PDUFA Action Date for HEPLISAV-B(TM)
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for HEPLISAV-B™, the company's vaccine candidate for immunization...
Mar 17, 2016 07:00 am ET
Dynavax Announces Data Presentations at AACR Annual Meeting
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present data at the American Association for Cancer Research Annual Meeting next month in New Orleans, Louisiana. The details for the poster presentations are as follows:...
Mar 08, 2016 07:00 am ET
Dynavax Reports Fourth Quarter and Year End 2015 Financial Results
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2015.The Company had $196.1 million in cash, cash equivalents and marketable securities as of December 31, 2015....
Mar 02, 2016 04:05 pm ET
Dynavax to Participate in the Cowen and Company 36th Annual Health Care Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast...
Feb 17, 2016 07:00 am ET
Dynavax to Participate in 2016 RBC Capital Markets Global Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will participate in a fireside chat at the RBC Capital Markets 2016 Global Healthcare Conference next week in New York, NY. The...
Jan 19, 2016 04:00 pm ET
Dynavax and AstraZeneca Amend Their Agreement for Asthma Drug Candidate
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company and AstraZeneca signed an amendment to their existing Research Collaboration and License Agreement under which, based on the strategic priorities of the two companies,...
Jan 11, 2016 04:43 pm ET
Dynavax to Present at J.P. Morgan 34th Annual Healthcare Conference
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will present at the J.P. Morgan 34th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday,...